{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T06:27:22Z","timestamp":1762928842128,"version":"3.40.5"},"reference-count":27,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T00:00:00Z","timestamp":1603670400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","award":["CRAD001LDE36T"],"award-info":[{"award-number":["CRAD001LDE36T"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>MARC\u20102, a prospective, multicenter phase IV trial, aimed to investigate clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with everolimus after failure of one initial vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR\u2010TKI) therapy and to identify subgroups benefiting most, based on clinical characteristics and biomarkers. Patients with clear cell mRCC failing one initial VEGFR\u2010TKI received everolimus until progression or unacceptable toxicity. Primary endpoint was 6\u2010month progression\u2010free survival rate (6moPFS). Secondary endpoints were overall response rate (ORR), PFS, overall survival (OS), and safety. Between 2011 and 2015, 63 patients were enrolled. Median age was 65.4\u2009years (range 43.3\u201081.1). 6moPFS was 39.3% (95% confidence interval [CI], 27.0\u201051.3) overall, 54.4% (95% CI, 35.2\u201070.1) vs 23.7% (95% CI, 10.5\u201039.9) for patients aged \u226565 vs &lt;65\u2009years and 51.4% (95% CI, 34.7\u201065.7) vs 18.2% (95% CI, 5.7\u201036.3) for patients with body mass index (BMI) &gt;25 vs \u226425\u2009kg\/m<jats:sup>2<\/jats:sup>. A Cox proportional hazards model confirmed a longer PFS for patients aged \u226565\u2009years (hazard ratio [HR] 0.46; 95% CI, 0.26\u20100.80) and a longer OS for patients with BMI &gt;25\u2009kg\/m<jats:sup>2<\/jats:sup> (HR 0.36; 95% CI, 0.18\u20100.71). Median PFS and median OS were 3.8 months (95% CI, 3.2\u20106.2) and 16.8 months (95% CI, 14.3\u201024.3). ORR was 7.9% and disease control rate was 60.3%. No new safety signals emerged. Most common adverse events were stomatitis (31.7%), fatigue (31.7%), and anemia (30.2%). One patient died from treatment\u2010related upper gastrointestinal hemorrhage. Everolimus remains a safe and effective treatment option for mRCC patients after one prior VEGFR\u2010TKI therapy. Patients aged \u226565\u2009years and patients with BMI &gt;25\u2009kg\/m<jats:sup>2<\/jats:sup> benefited most.<\/jats:p>","DOI":"10.1002\/ijc.33349","type":"journal-article","created":{"date-parts":[[2020,10,18]],"date-time":"2020-10-18T15:14:28Z","timestamp":1603034068000},"page":"1685-1694","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Everolimus after failure of one prior <scp>VEGF<\/scp>\u2010targeted therapy in metastatic renal cell carcinoma: Final results of the <scp>MARC<\/scp>\u20102 trial"],"prefix":"10.1002","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4574-6522","authenticated-orcid":false,"given":"Michael","family":"Staehler","sequence":"first","affiliation":[{"name":"Department of Urology, Interdisciplinary Center of Renal Tumors Ludwig\u2010Maximilians\u2010University of Munich  Munich Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"St\u00f6ckle","sequence":"additional","affiliation":[{"name":"Department of Urology and Paediatric Urology Saarland University Medical Center  Homburg (Saar) Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel C.","family":"Christoph","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology University Hospital Essen  Essen Germany"},{"name":"Department of Medical Oncology &amp; Hematology Evang. Kliniken Essen\u2010Mitte, Evang. Huyssens\u2010Stiftung Essen\u2010Huttrop  Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnulf","family":"Stenzl","sequence":"additional","affiliation":[{"name":"Department of Urology University Hospital Tuebingen  T\u00fcbingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Potthoff","sequence":"additional","affiliation":[{"name":"Medical Department iOMEDICO  Freiburg im Breisgau Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc\u2010Oliver","family":"Grimm","sequence":"additional","affiliation":[{"name":"Department of Urology University Hospital Jena  Jena Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dunja","family":"Klein","sequence":"additional","affiliation":[{"name":"Medical Department iOMEDICO  Freiburg im Breisgau Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Harde","sequence":"additional","affiliation":[{"name":"Biostatistics, iOMEDICO  Freiburg im Breisgau Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Br\u00fcning","sequence":"additional","affiliation":[{"name":"Department of Urology and Pediatric Urology Philipps\u2010University Marburg, University Hospital Giessen and Marburg GmbH  Marburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Goebell","sequence":"additional","affiliation":[{"name":"Department of Urology and Clinic for Haematology and Internistic Oncology University Hospital Erlangen, Ambulatory Uro\u2010Oncological Therapy Unit Erlangen (AURONTE)  Erlangen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marinela","family":"Augustin","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Klinikum Nuremberg, Paracelsus Medical University  N\u00fcrnberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederik","family":"Roos","sequence":"additional","affiliation":[{"name":"Department of Urology University Hospital Frankfurt  Frankfurt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Benz\u2010R\u00fcd","sequence":"additional","affiliation":[{"name":"Medical Department iOMEDICO  Freiburg im Breisgau Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6098-1301","authenticated-orcid":false,"given":"Norbert","family":"Marschner","sequence":"additional","affiliation":[{"name":"Outpatient\u2010Centre for Interdisciplinary Oncology and Haematology  Freiburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktor","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation University Hospital Hannover Medical School  Hannover Germany"},{"name":"Clinic for Internal Medicine (Tumour Research) and Clinic for Urology, West German Cancer Center University Hospital Essen  Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,10,26]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.07.030"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00290-9"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu259"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz056"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.9764"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816047"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30723-8"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_201215"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2016.06.020"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61039-9"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.11.027"},{"key":"e_1_2_11_13_1","unstructured":"Afinitor Tablets (eMC).https:\/\/www.medicines.org.uk\/emc\/medicine\/22281. Accessed January 26 2018."},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_11_15_1","unstructured":"CTCAE_4.02_2009\u201009\u201015_QuickReference_8.5x11.pdf [Internet].https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.02_2009-09-15_QuickReference_8.5x11.pdf. Accessed October 31 2019."},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(96)00075-X"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.15586\/jkcvhl.2017.59"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25219"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.12.057"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv612"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.3961"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70093-7"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2018.07.007"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30107-3"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604456"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn319"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.26.15_suppl.5095"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.33349","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijc.33349","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.33349","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T01:09:10Z","timestamp":1693616950000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.33349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,26]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1002\/ijc.33349"],"URL":"https:\/\/doi.org\/10.1002\/ijc.33349","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"type":"print","value":"0020-7136"},{"type":"electronic","value":"1097-0215"}],"subject":[],"published":{"date-parts":[[2020,10,26]]},"assertion":[{"value":"2020-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}